Hidden Consequences of Interim Analyses & Adaptive Trial Options
Por um escritor misterioso
Descrição
Frontiers OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany
Do we need to adjust for interim analyses in a Bayesian adaptive trial design?, BMC Medical Research Methodology
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer
European Urology Today Vol. 33 No.2 - March/May 2021 by European Association of Urology (EAU) - Issuu
Adaptive designs in clinical trials: why use them, and how to run and report them, BMC Medicine
HOPE-3 trial of DMD therapy CAP-1002 to continue as planned
The Missing Link – Handling Missing Data in Clinical Trials
Laser Focal Therapy - 10 Year Phase II Clinical Trial Results
Hidden Consequences of Interim Analyses & Adaptive Trial Options - Quantics Biostatistics
INSPIRED Symposium Part 4A: Access to CAR T Cell Therapy in Unique Populations with B Cell Acute Lymphoblastic Leukemia - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation
May/June 2022: Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial - ICAP at Columbia University
Hidden Consequences of Interim Analyses & Adaptive Trial Options
Key design considerations for adaptive clinical trials: a primer for clinicians
Guidance on interim analysis methods in clinical trials, Journal of Clinical and Translational Science
